[go: up one dir, main page]

WO1999031260A3 - Regulatory sequences involved in pancreas-specific gene expression - Google Patents

Regulatory sequences involved in pancreas-specific gene expression Download PDF

Info

Publication number
WO1999031260A3
WO1999031260A3 PCT/EP1998/008215 EP9808215W WO9931260A3 WO 1999031260 A3 WO1999031260 A3 WO 1999031260A3 EP 9808215 W EP9808215 W EP 9808215W WO 9931260 A3 WO9931260 A3 WO 9931260A3
Authority
WO
WIPO (PCT)
Prior art keywords
regulatory sequences
vectors
recombinant dna
dna molecules
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1998/008215
Other languages
French (fr)
Other versions
WO1999031260A2 (en
Inventor
Peter Gruss
Birgitta Kammandel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority to AU20539/99A priority Critical patent/AU2053999A/en
Publication of WO1999031260A2 publication Critical patent/WO1999031260A2/en
Publication of WO1999031260A3 publication Critical patent/WO1999031260A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Described are regulatory sequences of the promoter of the Pax6 gene or a gene homologous to the Pax6 gene, being capable of conferring expression in pancreatic cells. Recombinant DNA molecules and vectors comprising said regulatory sequences as well as to host cells transformed therewith. Described are also pharmaceutical and diagnostic compositions comprising such regulatory sequences, recombinant DNA molecules and vectors. Furthermore, transgenic non-human animals, comprising the afore-mentioned recombinant DNA molecules or vectors stably integrated into their genome. Also provided are uses of the before described recombinant DNA molecules and vectors for the preparation of pharmaceutical compositions for treating, preventing and/or delaying a disease related to the pancreas in a subject. Furthermore, uses of the regulatory sequences, the recombinant DNA molecules and vectors of the invention for the preparation of pharmaceutical compositions for inducing a pancreatic disease in a non-human animal are provided. Additionally a method for identifying agonists/activators or antagonists/inhibitors of genes or gene products involved in pancreatic diseases employing the above mentioned regulatory sequences, recombinant DNA molecules, vectors, cells and non-human transgenic animals, to compounds identifyable by said method, to antibodies directed to said compounds as well as to pharmaceutical and diagnostic compositions comprising said agonists/activators, antagonists/inhibitors and/or antibodies.
PCT/EP1998/008215 1997-12-15 1998-12-15 Regulatory sequences involved in pancreas-specific gene expression Ceased WO1999031260A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU20539/99A AU2053999A (en) 1997-12-15 1998-12-15 Regulatory sequences involved in pancreas-specific gene expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97122103.1 1997-12-15
EP97122103 1997-12-15

Publications (2)

Publication Number Publication Date
WO1999031260A2 WO1999031260A2 (en) 1999-06-24
WO1999031260A3 true WO1999031260A3 (en) 1999-08-12

Family

ID=8227804

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/008215 Ceased WO1999031260A2 (en) 1997-12-15 1998-12-15 Regulatory sequences involved in pancreas-specific gene expression

Country Status (2)

Country Link
AU (1) AU2053999A (en)
WO (1) WO1999031260A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028184A (en) * 1996-12-31 2000-02-22 Max-Plank-Gesellschaft Zur Forderung Der Wissenschaften E.V. Pax6 and Pax4 nucleic acid mixtures
US6337392B1 (en) 1998-05-07 2002-01-08 The Rockefeller University Lens transcriptional control elements and methods of use thereof
WO1999057294A1 (en) * 1998-05-07 1999-11-11 The Rockefeller University Lens transcriptional control elements and methods of use thereof
EP1567644A4 (en) * 2002-04-16 2006-04-05 Origene Technologies Inc Tissue specific genes and gene clusters
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
CN111202847B (en) * 2020-02-08 2021-11-30 北京大学第三医院（北京大学第三临床医学院） Application of PAX6 gene or its expression product in preparing medicine for inhibiting fibrosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5416017A (en) * 1990-05-18 1995-05-16 The Scripps Research Institute Cholera toxin gene regulated by tissue-specific promoters

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5416017A (en) * 1990-05-18 1995-05-16 The Scripps Research Institute Cholera toxin gene regulated by tissue-specific promoters

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002104751, Database accession no. Z95332 *
KAMMANDEL B. ET AL.: "Distinct cis-essential modules direct the time-space pattern of the Pax6 gene activity", DEVELOPMENTAL BIOLOGY, vol. 205, no. 1, 1 January 1999 (1999-01-01), pages 79 - 97, XP002105021 *
MILES C. ET AL.: "Complete sequencing of the Fugu WAGR region from WT1 to PAX6: dramatic compaction and conservation of synteny with human chromosome 11p13", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 95, October 1998 (1998-10-01), pages 13068 - 13072, XP002104750 *
PLAZA S. ET AL.: "Quail PAX-6 (PAX-QNR) encodes a transcription factor able to bind and trans-activate its own promoter", CELL GROWTH & DIFFERENTIATION, vol. 4, December 1993 (1993-12-01), pages 1041 - 1050, XP002104749 *
ST-ONGE L. ET AL.: "Pax6 is required for differentiation of glucacon-producing alpha-cells in mouse pancreas", NATURE, vol. 387, 22 May 1997 (1997-05-22), pages 406 - 409, XP002067724 *
TURQUE N. ET AL.: "Pax-QNR/Pax-6, a paired box- and homeobox-containing gene expressed in neurons, is also expressed in pancreatic endocrine cells", MOLECULAR ENDOCRINOLOGY, vol. 8, no. 7, 1 July 1994 (1994-07-01), pages 929 - 938, XP002067722 *
XU P.-X. ET AL.: "Regulation of Pax6 expression is conserved between mice and flies", DEVELOPMENT, vol. 126, no. 2, January 1999 (1999-01-01), pages 383 - 395, XP002105022 *

Also Published As

Publication number Publication date
WO1999031260A2 (en) 1999-06-24
AU2053999A (en) 1999-07-05

Similar Documents

Publication Publication Date Title
Lee Extracellular regulation of myostatin: a molecular rheostat for muscle mass
WO2002000730A3 (en) Pd-l2 molecules: novel pd-1 ligands and uses therefor
DE60035517D1 (en) GL50 MOLECULES, AND USES THEREOF
ATE269402T1 (en) IKK-BETA PROTEINS, NUCLEIC ACIDS AND METHODS
WO2001073060A3 (en) 18221, dual specificity phosphatase and uses thereof
WO2003042362A8 (en) PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR
ATE300619T1 (en) HUMAN CHECKPOINT KINASE, HCDS1, COMPOSITIONS AND METHODS
CA2385444A1 (en) Humanin, a polypeptide suppressing neuronal death
WO1999031260A3 (en) Regulatory sequences involved in pancreas-specific gene expression
DE69832798D1 (en) REGULATORY SEQUENCES FOR THE IN VIVO EXPRESSION OF A HETEROLOGICAL DNA SEQUENCE IN ENDOTHELIAL CELLS AND THEIR USES.
WO2000077239A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2003004613A3 (en) Novel pgc-1 isoforms and uses therefor
WO2001076457A3 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
DE60142356D1 (en) 18480 HUMAN PROTEIN KINASEMOLEKÜLE AND ITS USES
WO2003018829A3 (en) 6299, a human zinc carboxypeptidase family member and uses therefor
WO2004039307A3 (en) Methods and compositions for diagnosing and treating companion animal cancer
WO2003020913A3 (en) Anopheles gambiae odorant receptors and genes
WO2001000638A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2001066765A3 (en) 26583, a serine/threonine phosphatase and uses thereof
WO2003020912A3 (en) Novel clark protein and nucleic acid molecules and uses therefor
WO2001066763A3 (en) 23436, a human ubiquitin protease family member and uses thereof
WO2001064911A3 (en) 18232, a dual specificity phosphatase
WO2002016588A3 (en) 15985, a human serine/threonine protein kinase family membe r and uses thereof
WO2001073050A3 (en) 3714, 16742, 23546, and 13887 novel protein kinase molecules and uses therefor
WO2001081588A3 (en) 2246, novel protein kinase molecules and uses therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase